Pivotal Therapeutics Inc. Announces First Quarter 2013 Financial Results
5/29/2013 11:06:30 AM
More...
|
Pivotal Therapeutics Inc. Research Update Released
5/17/2013 9:39:46 AM
More...
|
Pivotal Therapeutics Inc. VASCAZEN®-REVEAL Trial Meets Primary and Secondary Endpoints - VASCAZEN® Shows 121% Correction of an Omega-3 Deficiency (P< 0.0001) With a Concomittant 48% Reduction in Triglycerides (P<0.0005)
5/7/2013 10:04:22 AM
More...
|
Pivotal Therapeutics Inc. VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions
5/1/2013 6:56:08 AM
More...
|
Pivotal Therapeutics Inc. VASCAZEN® - Meets Primary Endpoint in Reveal Trial - Top Line Results Accepted for Presentation at the American Heart Association's ATVB 2013 Scientific Sessions
4/9/2013 9:24:16 AM
More...
|
Pivotal Therapeutics Inc. Reports Third Quarter 2012 Financial Results
11/30/2012 8:28:33 AM
More...
|
Pivotal Therapeutics Inc. Exhibiting at the 2012 Cardiometabolic Health Congress
10/10/2012 11:08:35 AM
More...
|
Pivotal Therapeutics Inc. to Present at Rodman & Renshaw Annual Global Investment Conference
9/7/2012 10:52:45 AM
More...
|
Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012
9/5/2012 11:01:13 AM
More...
|
Pivotal Therapeutics Inc. Reports Second Quarter 2012 Financial Results
8/29/2012 10:50:14 AM
More...
|
|